These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31475951)

  • 1. Visit-to-visit variability in low-density lipoprotein cholesterol is associated with adverse events in non-obstructive coronary artery disease.
    Gu J; Yin ZF; Pan JA; Zhang JF; Wang CQ
    Anatol J Cardiol; 2019 Sep; 22(3):117-124. PubMed ID: 31475951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visit-to-visit variability in LDL- and HDL-cholesterol is associated with adverse events after ST-segment elevation myocardial infarction: A 5-year follow-up study.
    Boey E; Gay GM; Poh KK; Yeo TC; Tan HC; Lee CH
    Atherosclerosis; 2016 Jan; 244():86-92. PubMed ID: 26595903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of visit-to-visit LDL-, HDL-, and non-HDL-cholesterol variability on mortality and cardiovascular outcomes after percutaneous coronary intervention.
    Lee EY; Yang Y; Kim HS; Cho JH; Yoon KH; Chung WS; Lee SH; Chang K
    Atherosclerosis; 2018 Dec; 279():1-9. PubMed ID: 30359786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visit-to-visit variability of lipid measurements as predictors of cardiovascular events.
    Waters DD; Bangalore S; Fayyad R; DeMicco DA; Laskey R; Melamed S; Barter PJ
    J Clin Lipidol; 2018; 12(2):356-366. PubMed ID: 29310989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial.
    Bangalore S; Breazna A; DeMicco DA; Wun CC; Messerli FH;
    J Am Coll Cardiol; 2015 Apr; 65(15):1539-48. PubMed ID: 25881936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obstructive sleep apnea is associated with visit-to-visit variability in low-density lipoprotein-cholesterol in patients with coronary artery disease.
    Ng G; Boey E; Frampton C; Richards AM; Yeo TC; Lee CH
    Sleep Breath; 2017 May; 21(2):271-278. PubMed ID: 27502204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visit-to-visit variability of lipid measurements and the risk of myocardial infarction and all-cause mortality: A prospective cohort study.
    Liu X; Wu S; Song Q; Wang X
    Atherosclerosis; 2020 Nov; 312():110-116. PubMed ID: 32958454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients With Manifest Arterial Disease.
    van den Berg MJ; van der Graaf Y; de Borst GJ; Kappelle LJ; Nathoe HM; Visseren FLJ;
    Am J Cardiol; 2016 Sep; 118(6):804-810. PubMed ID: 27471056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial.
    Bangalore S; Fayyad R; Messerli FH; Laskey R; DeMicco DA; Kastelein JJ; Waters DD
    Am J Cardiol; 2017 Feb; 119(3):379-387. PubMed ID: 27939230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visit-to-visit cholesterol variability correlates with coronary atheroma progression and clinical outcomes.
    Clark D; Nicholls SJ; St John J; Elshazly MB; Kapadia SR; Tuzcu EM; Nissen SE; Puri R
    Eur Heart J; 2018 Jul; 39(27):2551-2558. PubMed ID: 29688308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of low-density lipoprotein pattern with mortality after myocardial infarction: Insights from the TRIUMPH study.
    Pokharel Y; Tang Y; Bhardwaj B; Patel KK; Qintar M; O'Keefe JH; Kulkarni KR; Jones PH; Martin SS; Virani SS; Spertus JA
    J Clin Lipidol; 2017; 11(6):1458-1470.e4. PubMed ID: 29050980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of high-density lipoprotein cholesterol with periprocedural myocardial injury following elective percutaneous coronary intervention in patients with low-density lipoprotein cholesterol below 70 mg/dL.
    Li XL; Guo YL; Zhu CG; Xu RX; Qing P; Wu NQ; Jiang LX; Xu B; Gao RL; Li JJ
    J Am Heart Assoc; 2015 Jan; 4(1):e001412. PubMed ID: 25572484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated small dense low-density lipoprotein cholesterol as a predictor for future cardiovascular events in patients with stable coronary artery disease.
    Nishikura T; Koba S; Yokota Y; Hirano T; Tsunoda F; Shoji M; Hamazaki Y; Suzuki H; Itoh Y; Katagiri T; Kobayashi Y
    J Atheroscler Thromb; 2014; 21(8):755-67. PubMed ID: 24717762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
    Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ
    Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease.
    Xu RX; Zhang Y; Li XL; Li S; Guo YL; Dong Q; Liu G; Li JJ
    Clin Chim Acta; 2015 Jun; 446():195-200. PubMed ID: 25934512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2.
    Natsuaki M; Furukawa Y; Morimoto T; Nakagawa Y; Ono K; Kaburagi S; Inada T; Mitsuoka H; Taniguchi R; Nakano A; Kita T; Sakata R; Kimura T;
    Circ J; 2012; 76(6):1369-79. PubMed ID: 22447012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.
    Nakamura T; Obata JE; Hirano M; Kitta Y; Fujioka D; Saito Y; Kawabata K; Watanabe K; Watanabe Y; Mishina H; Kugiyama K
    Atherosclerosis; 2011 Sep; 218(1):163-7. PubMed ID: 21605862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reaching low-density lipoprotein cholesterol treatment targets in stable coronary artery disease: Determinants and prognostic impact.
    Bauters C; Tricot O; Lemesle G; Meurice T; Hennebert O; Farnier M; Lamblin N
    Arch Cardiovasc Dis; 2018 Nov; 111(11):634-643. PubMed ID: 29198936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum high-density lipoprotein-cholesterol levels modify the association between plasma levels of oxidatively modified low-density lipoprotein and coronary artery disease in men.
    Zhang B; Bai H; Liu R; Kumagai K; Itabe H; Takano T; Saku K
    Metabolism; 2004 Apr; 53(4):423-9. PubMed ID: 15045686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy.
    Ndrepepa G; Braun S; Tada T; Guerra E; Schunkert H; Laugwitz KL; Kastrati A
    Cardiovasc Revasc Med; 2014 Apr; 15(3):131-6. PubMed ID: 24630704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.